Tag 'pharmacovigilance'

In the evolving landscape of pharmacovigilance, signal management has become a central pillar in ensuring drug safety and maintaining compliance with global regulatory affairs…

Ensuring business continuity in pharmacovigilance operations is essential for safeguarding public health by continuously monitoring the safety of medicinal products. Any disruption in PV…

Pharmacovigilance (PV) has traditionally relied on spontaneous reporting systems, clinical trial data, and published literature to monitor the safety of medicinal products. However, the…

Drug safety, is a critical component of the healthcare and pharmaceutical industries. It focuses on detecting, assessing, understanding, and preventing adverse effects or any…

Pharmacovigilance (PV) systems are designed to ensure the continuous monitoring of the safety of medicinal products throughout their lifecycle. In a highly regulated environment, organizations…

Medicines are developed to prevent, treat, and manage diseases but no medicine is entirely without risk. While clinical research trials provide essential safety and…

The European Medicines Agency (EMA) has introduced three new features under its PRIME scheme to enhance the development of medicines targeting unmet medical needs.…

The Spanish Agency for Medicines and Health Products (AEMPS) has published the annual report of the Spanish Pharmacovigilance System for Medicines for Human Use…

Pharmacovigilance (PV) is a cornerstone of patient safety and regulatory compliance. While timely processing of Individual Case Safety Reports (ICSRs) is a regulatory requirement,…

The U.S. Food and Drug Administration announced on March 11, 2026, the launch of a new unified platform for analyzing adverse event reports. The…

Corrective and Preventive Action (CAPA) management is one of the most critical pillars of an effective pharmacovigilance (PV) system. Regulatory inspections—whether conducted by local…

Managing safety signals in rare diseases presents unique and complex challenges for pharmacovigilance (PV) systems worldwide. Limited patient populations, scarce clinical data, and heterogeneous…

As pharmaceutical companies expand into global markets, pharmacovigilance (PV) systems become increasingly complex. While global PV frameworks provide consistency and oversight, patient safety is…

Under the EU Good Pharmacovigilance Practices (GVP), Marketing Authorization Holders (MAHs) are required to maintain a fully functioning, compliant, and continuously monitored Pharmacovigilance (PV)…

The Therapeutic Goods Administration (TGA) of Australia has completed an upgrade of its internal Adverse Event Management System (AEMS) by transitioning the database to a…